Other studies suggested that HRG1β-based CAR-T cells successfully inhibit breast cancer proliferation through HER family receptors and able to deliver an attractive therapeutic approach to defeat cancer resistance against HER2-based targeted therapy [62]. Here, ERBB2 is linked to breast cancer.